AstraZeneca yakagamuchira kukwidziridzwa kwakapetwa kaviri kweiyo oncology portfolio neChipiri, mushure mekunge US neEuropean regulators vabvuma kutumirwa kwemishonga yavo, danho rekutanga rekuhwina mvumo yemishonga iyi.
Anglo-Swedish drugmaker, uye MedImmune, iyo yepasi rose biologics research and development arm, yakazivisa kuti US Food and Drug Administration (FDA) yatambira rezinesi rekushandisa moxetumomab pasudotox, mushonga mutsva unogona kurapwa kwevarwere vakuru vane mvere sero. leukemia (HCL) avo vakagamuchira mitsara miviri yapfuura yekurapa.
Iyo FDA yakapa mushonga "yekutanga ongororo" chimiro, icho chinopihwa kumishonga iyo, kana ikabvumidzwa, inopa kuvandudzwa kwakakura mukurapa, kuongororwa, kana kudzivirira kwemamiriro akakomba. Sarudzo inotarisirwa muchikamu chechitatu chegore rino.
Neparutivi, European Medicines Agency yakabvuma kutumirwa kweLynparza, mushonga uyo AstraZeneca yave muridzi we50:50 mukudyidzana neMerck, iyo kambani yemishonga yeUS, kurapa gomarara rezamu iro rakapararira kumwe kunhu mumuviri kune varwere vane imwe. genetic mutation.
Kana ikabvumidzwa, mushonga unozova wekutanga PARP inhibitor yekurapa kenza yemazamu muEurope. PARP iprotein inowanikwa mumasero evanhu iyo inobatsira masero iwayo kuti azvigadzirise kana akanganiswa. Nekumisa maitiro ekugadzirisa aya mumasero egomarara, PARP inhibitors anobatsira sero kufa.
Lynparza muna Ndira yakava yekutanga PARP inhibitor yakabvumidzwa chero pasirese gomarara rezamu, apo yakahwina kuenda-mberi kubva kuUS regulators.
Muyedzo ichangoburwa, Lynparza akawedzera zvakanyanya kufambira mberi-pasina kupona kana zvichienzaniswa nechemotherapy uye akadzikisa njodzi yekukura kwechirwere kana kufa ne42 muzana.
Muna 2017 chikamu chechishanu chekutengeswa kwechigadzirwa cheAstra chaibva kuoncology uye kambani inotarisira kuti chikamu ichi chichakwira. Migove muboka yakavhara 0.6 muzana pa £49.26.
Mune imwe budiriro, Compugen, kambani yeIsrael pharma, yakati yakapinda muchibvumirano cherezinesi chega neMedImmune icho chichagonesa kugadzirwa kwezvigadzirwa zvemaantibody kurapa gomarara.
MedImmune ine kodzero yekugadzira zvigadzirwa zvakawanda pasi perezinesi "uye ichave ine mutoro wezvese kutsvagisa, kusimudzira uye zvekutengesa zviitiko pasi pechibvumirano", Compugen akadaro.
Kambani yeIsrael ichawana $10m yekubhadhara mberi uye inokodzera kugamuchira kusvika ku $200m mukusimudzira, kutonga uye kutengeserana kwekutanga kwechigadzirwa, pamwe nemari yekubhadhara mune ramangwana rekutengesa chigadzirwa.
Anat Cohen-Dayag, mukuru weCompugen, akati chibvumirano ichi "chinotibvumira kuita mari yekufambira mberi kwesainzi muzvirongwa zvedu, isu tichienderera mberi nekusimudzira zvirongwa zvedu zvinotungamira mumiedzo yekiriniki".
Nguva yekutumira: Kubvumbi-23-2018